For patients with cutaneous sarcoidosis (CS), brepocitinib is associated with dose-dependent and clinically meaningful improvements, according to a study published online in JAMA Dermatology to coincide with the annual meeting of the American College of Rheumatology, held from Nov. 6 to 11 in Orlando, Florida.
Brepocitinib yields improvements in cutaneous sarcoidosis
This article reports on a medical study showing that brepocitinib, a drug treatment, provides dose-dependent improvements for patients with cutaneous sarcoidosis. The study was presented at the American College of Rheumatology annual meeting in Orlando, Florida. This article contains no information related to Iran, Iranian politics, economics, military affairs, or international relations.
🏷️ Entities Mentioned
Translated from the original and edited for English readers. View original source →
Translation confidence: 100%